Clinical trial
Real-World Outcomes of Ofatumumab: Relapse Rates, Disease Progression, and Treatment Patterns in Germany and Japan
NCT07821411 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-World Outcomes of Ofatumumab: Relapse Rates, Disease Progression, and Treatment Patterns in Germany and Japan
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- July 31, 2026
- Completion date
- September 30, 2026
- Enrollment
- 5,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.